# Trial Ruxolitinib and Peg-interferon Alpha-2a Combination in Patients With Primary Myelofibrosis RUXOPeg

> **NCT02742324** · PHASE1,PHASE2 · COMPLETED · sponsor: **French Innovative Leukemia Organisation** · enrollment: 37 (actual)

## Conditions studied

- Myelofibrosis

## Interventions

- **DRUG:** Ruxolotinib
- **DRUG:** peg-IFN alpha -2a

## Key facts

- **NCT ID:** NCT02742324
- **Lead sponsor:** French Innovative Leukemia Organisation
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03
- **Primary completion:** 2021-12-30
- **Final completion:** 2021-12-31
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2022-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02742324

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02742324, "Trial Ruxolitinib and Peg-interferon Alpha-2a Combination in Patients With Primary Myelofibrosis RUXOPeg". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02742324. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*